Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
About this study
The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.
- Condition
- Acute Lymphoblastic Leukemia, Pediatric
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Who can join
- Age
- 0.08 to 18 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 0.08 years
- Maximum age: 18 years
- Study condition: Acute Lymphoblastic Leukemia, Pediatric
- Age at diagnosis ranging from 1 month to 18 years.
- Positive for the BCR::ABL fusion gene.
- Serial quantitative MRD testing was routinely performed using multiparameter flow cytometry (MFC) and PCR (qRT-PCR or ddPCR) during treatment, with samples collected for both assays at identical time points.
- Standardized TKI therapy (imatinib, dasatinib, or other TKIs) was administered.
Exclusion 4
- Mixed-phenotype acute leukemia.
- Irregular treatment not administered in accordance with the chemotherapy protocol.
- Previous or concurrent other malignancies.
- Failure to receive standardized TKI therapy due to intolerance to TKIs, contraindications to TKI treatment, or other relevant factors.
Where
1 site, 1 recruiting
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact
-
Aimei Ma
+86-571-86670076 zuchiec@163.com
Potential match only. Final eligibility is determined by the study team.